
Sumitomo Pharma America Unveils First Clinical Findings for Investigational CHK1 Inhibitor SMP-3124LP at ASCO 2026
Sumitomo Pharma America Reports Promising Early Clinical Results for Investigational CHK1 Inhibitor SMP-3124LP in Advanced Solid Tumors Sumitomo Pharma America, Inc. (SMPA) has unveiled encouraging clinical findings from its ongoing…












